http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2009513640-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D487-04 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4985 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D487-04 |
| filingDate | 2006-10-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2009-04-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-2009513640-A |
| titleOfInvention | HIV integrase inhibitor |
| abstract | Formula (I) The substituted hydroxytetrahydropyrrolopyrazinone and substituted hydroxytetrahydro-pyrazolopyrazinone compounds are inhibitors of HIV integrase and inhibitors of HIV replication. R 1 , R 2 , R 3 , R 4 , R 5 , X, ring A and Q in formula (I) are defined in the text. The compounds are useful for the prevention and treatment of HIV infection, the prevention, delay and treatment of AIDS. The compound is used against HIV infection and AIDS as the compound itself or in the form of a pharmaceutically acceptable salt. The compounds and their salts can be used as ingredients in pharmaceutical compositions, optionally in combination with other antiviral agents, immunomodulators, antibiotics or vaccines. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-WO2015129821-A1 |
| priorityDate | 2005-10-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 191.